WHO WE ARE
Zunity Health Inc. is a startup biotech company that is dedicated to employ an unconventional strategy to develop novel cancer therapies. Contrary to the traditional approaches that target specific pathological pathways, we focus on promoting physiological health for cancer intervention. By leveraging our expertise in the area of homeostasis regulation, we aim to develop first-in-class therapeutic agents that can boost and sustain biological robustness and resilience. Our goal is to revolutionize the biomedicine field by developing therapeutics that treat cancer via bolstering physiological health.
Scientific advisory board:
Dr. Dieter A. Wolf, Professor. Institute of Molecular Oncology and Functional Genomics and Center for Translational Caner Research, School of Medicine, Technical University of Munich, Munich 81675, Germany.
Dr. Dieter A. Wolf, Professor. Institute of Molecular Oncology and Functional Genomics and Center for Translational Caner Research, School of Medicine, Technical University of Munich, Munich 81675, Germany.
Dr. Dmitri Wiederschain, Chief Scientific Officer, Jounce Therapeutics, Cambridge, MA.
Dr. Carl Maki, Professor, Department of Anatomy & Cell Biology, Rush Medical College, Chicago.
Dr. Chuanyuan Li, Professor, Department of Dermatology, Duke University School of Medicine, North Carolina.
Dr. Jijie Gu, Chief Scientific Officer, Wuxi Biologics.
Dr. Xinbin Chen, Professor, Department of Surgical & Radiological Sciences, UC Devis School of Veterinary Medicine, CA
